Skip to main content

Vanguard Group Inc

SEC CIK
0000102909
Latest filing
Jan 29, 2026

RXDX holding history

Prometheus Biosciences, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

RXDX overviewAll 13F holders of RXDXFull Q4 2025 holdings

Shares (Q2 2023)
0
Sold out in Q2 2023
Value
$0
% of portfolio
0.0%
Quarters held
9
Since Q1 2021
Holdings of RXDX by Vanguard Group Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20230$00.0%−2,716,901−100.0%Sold outHolders
Q1 20232,716,901$291.6M<0.1%+860,646+46.4%AddedHolders
Q4 20221,856,255$204.2M<0.1%+294,649+18.9%AddedHolders
Q3 20221,561,606$92.2M<0.1%+328,397+26.6%AddedHolders
Q2 20221,233,209$34.8M<0.1%+31,667+2.6%AddedHolders
Q1 20221,201,542$45.4M<0.1%+8,700+0.7%AddedHolders
Q4 20211,192,842$47.2M<0.1%+649,933+119.7%AddedHolders
Q3 2021542,909$12.9M<0.1%+3,548+0.7%AddedHolders
Q2 2021539,361$13.2M<0.1%+419,361+349.5%AddedHolders
Q1 2021120,000$2.19M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.